Craig-Hallum analyst Alex Nowak raised the firm’s price target on Exact Sciences to $44 from $35 and keeps a Hold rating on the shares. The analyst notes that the company’s management has sounded increasingly better throughout 2022 and it culminated in a strong Q4 preliminary result. Cologuard generated what appears to be clean upside and Precision Oncology largely in-line with his estimate. For the full-year, Cologuard sales should end around +34% year-over-year, notable given the company’s push towards adjusted profitability at the same time, Nowak adds.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on EXAS:
- Exact reports preliminary Q4 revenue $550.7M-$552.7M, consensus $506.48M
- Exact Sciences Announces Preliminary Fourth Quarter 2022 Results
- EXACT Sciences put volume heavy and directionally bearish
- Cathie Wood’s Crystal Ball Calls for Big Jump on EXAS
- ‘Innovation Stocks Will Eventually Win’: Here Are Cathie Wood’s Top Holdings and Where They Are Headed
